Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03699917 · ClinicalTrials.gov registry record
Goal-directed Fluid Therapy on Complications After Pancreaticoduodenectomy
A clinical trial, sponsored by Wake Forest University Health Sciences.
- Completed
- Registry status
- 64
- Enrollment target
NCT03699917: Completed study, sponsored by Wake Forest University Health Sciences.
NCT03699917 is a clinical trial that has completed, run by Wake Forest University Health Sciences. The registered enrollment target is 64 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03699917 has completed, sponsored by Wake Forest University Health Sciences.
- COMPLETED
- Registry status
- 64 participants
- Enrollment target
Study Summary
Optimal fluid balance is critical to minimize anastomotic edema in patients undergoing pancreaticoduodenectomy. This study examined the effects of decreased fluid administration on rates of postoperative pancreatic leak and delayed gastric emptying.
Primary Outcome
Number of patients with postoperative pancreatic leak and postoperative delayed gastric emptying. Stroke volume is calculated using measurements of ventricle volumes from an echocardiogram and subtracting the volume of the blood in the ventricle at the end of a beat (called end-systolic volume) from the volume of blood just prior to the beat (called end-diastolic volume).
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2015-01-01 |
| Est. Completion | 2016-07-31 |
What the finished NCT03699917 record still lists
NCT03699917 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 64 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT03699917 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03699917 about?
NCT03699917 is a clinical study titled "Goal-directed Fluid Therapy on Complications After Pancreaticoduodenectomy". Optimal fluid balance is critical to minimize anastomotic edema in patients undergoing pancreaticoduodenectomy. This study examined the effects of decreased fluid administration on rates of postoperative pancreatic leak and delayed gastric emptying.
What is the current status of trial NCT03699917?
This trial is currently completed. The enrollment target is 64 participants. The study started on 2015-01-01. Estimated completion is 2016-07-31.
Who is sponsoring clinical trial NCT03699917?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01853631 · 64 participants · Phase 1
Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
- NCT03739502 · 64 participants · Phase 2
A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplant
- NCT03739814 · 64 participants · Phase 2
Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
- NCT03866408 · 64 participants · Early Phase 1
Insulin Regulation of Lipolysis and Lipolysis Proteins
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI